Showing results (81-90 of 116) with videos related to

Sort By:
Pageof 12
Thoracic Cancer|September 5, 2019
High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancerMari Tone, Takehiro Izumo, Nobuyasu Awano, et al.
ERJ Open Research|July 1, 2021
Body mass index and in-hospital mortality in patients with acute exacerbation of idiopathic pulmonary fibrosisNobuyasu Awano, Taisuke Jo, Hideo Yasunaga, et al.
Journal of Intensive Care|October 11, 2023
Polymyxin B-immobilised fibre column treatment for acute exacerbation of idiopathic pulmonary fibrosis patients with mechanical ventilation: a nationwide observational studyNobuyasu Awano, Taisuke Jo, Takehiro Izumo, et al.
Translational Lung Cancer Research|July 17, 2025
Natural course of lung adenocarcinoma manifesting as ground-glass nodules: invasiveness assessment based on growth evaluationYuanhui Wei, Zhen Yang, Zirui Wang, et al.
Respiratory Medicine Case Reports|November 2, 2020
The 2014 autochthonous dengue fever outbreak in Tokyo: A case series study and assessment of the causes and preventive measuresMayuko Kori, Nobuyasu Awano, Minoru Inomata, et al.
Respiratory Investigation|July 2, 2021
Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in JapanTakehiro Izumo, Naoyuki Kuse, Nobuyasu Awano, et al.
Japanese Journal of Clinical Oncology|January 28, 2021
Medical costs of Japanese lung cancer patients during end-of-life careNobuyasu Awano, Takehiro Izumo, Minoru Inomata, et al.
Japanese Journal of Clinical Oncology|October 6, 2017
Efficacy and safety of stereotactic body radiotherapy using CyberKnife in Stage I primary lung tumorNobuyasu Awano, Soichiro Ikushima, Takehiro Izumo, et al.
Japanese Journal of Clinical Oncology|January 28, 2021
Medical costs of lung cancer care in Japan during the first one or two years after initial diagnosisNobuyasu Awano, Takehiro Izumo, Minoru Inomata, et al.
Respiratory Investigation|August 20, 2021
Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19Takehiro Izumo, Naoyuki Kuse, Nobuyasu Awano, et al.
Pageof 12